• Takeda secured FDA clearance for MIMRYLO (rusfertide) to treat erythrocytosis in adults with polycythemia vera.
• Approval positions a first-in-class hepcidin mimetic to help keep hematocrit below 45%, a key clinical target in PV.
• Decision backed by the Phase 3 VERIFY trial in 293 patients, showing improved hematocrit control with fewer phlebotomies versus placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260824773270) on August 28, 2026, and is solely responsible for the information contained therein.